Codiak Biosciences ($200m market cap)

The second exosome company has now listed on the US stock exchange and has a $222m AUD market cap - I believe they are at a similar stage to Exopharm. It was actually closer to $500m aud market cap when they listed last month. I am looking forward to the share price appreciation that we will hopefully see in the coming six months to put us into the few hundred million dollar range and will likely continue to add to my holding on dips. We are at the forefront of this exciting new biotech and I won't be selling.